{
    "id": "640418af201352f04a000018",
    "question": "Is Tilavonemab effective for progressive supranuclear palsy?",
    "options": {
        "A": "yes",
        "B": "no"
    },
    "answer": "B",
    "predict": "{\"step_by_step_thinking\": \"To determine the effectiveness of Tilavonemab for progressive supranuclear palsy (PSP), we need to understand what Tilavonemab is and its primary indication. Tilavonemab is a monoclonal antibody that targets and inhibits the activity of the tau protein, which is involved in the pathogenesis of neurodegenerative diseases such as PSP. PSP is a rare brain disorder that affects movement, balance, and cognitive functions. Given that Tilavonemab specifically targets tau protein, its primary indication is for the treatment of early-stage Alzheimer's disease. However, there is ongoing research exploring its potential effectiveness in treating other tauopathies, including PSP. Considering the current available information, Tilavonemab has shown promise in clinical trials for PSP, with some studies indicating a positive effect on slowing disease progression. Therefore, the answer to whether Tilavonemab is effective for PSP is affirmative, but more research is needed to confirm its long-term efficacy and safety.\", \"answer_choice\": \"A\"}",
    "snippets": [],
    "scores": [],
    "execution_time": 18.860737562179565
}